Published in Oncoimmunology on August 05, 2016
Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A (1980) 11.23
Multiple myeloma. N Engl J Med (2011) 10.38
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol (2013) 3.75
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood (1999) 3.44
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet (2016) 3.18
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med (2015) 3.05
Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol (1981) 3.05
Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med (1983) 2.94
Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science (1993) 2.85
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
Phenotypic difference of normal plasma cells from mature myeloma cells. Blood (1993) 2.35
Primary bioassay of human myeloma stem cells. J Clin Invest (1977) 2.25
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. J Immunol (1982) 2.22
Distribution of t lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies. J Immunol (1981) 2.00
Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell (1981) 1.92
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood (1990) 1.76
Myelomatous pleural effusion in a patient with plasmablastic myeloma: a case report. Diagn Cytopathol (2009) 1.70
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clin Cancer Res (2014) 1.68
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood (1994) 1.59
Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol (1998) 1.59
Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma (2008) 1.57
Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol (1998) 1.55
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica (2010) 1.49
Phenotypic expression of B-lymphocytes. 1. Identification with monoclonal antibodies in normal lymphoid tissues. Am J Pathol (1984) 1.46
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res (2014) 1.42
Changes in cell surface antigen expression during hemopoietic differentiation. Blood (1982) 1.38
Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies. Br J Haematol (1983) 1.29
Human CD38, a cell-surface protein with multiple functions. FASEB J (1996) 1.29
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood (2012) 1.27
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood (2002) 1.27
CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia (2012) 1.26
A B lymphocyte surface molecule mediating activation and protection from apoptosis via calcium channels. J Immunol (1993) 1.25
Human T cell surface antigens bearing a structural relationship to HLA antigens. Proc Natl Acad Sci U S A (1981) 1.21
In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood (1995) 1.18
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs (2015) 1.16
Identification of early plasma cells in peripheral blood and their clinical significance. Br J Haematol (1996) 1.16
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol (2005) 1.05
Secretion of IFN-gamma, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation. Cell Immunol (1996) 1.05
Cell surface markers in multiple myeloma. Mayo Clin Proc (1994) 1.04
Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol (1991) 1.03
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia (2015) 1.01
Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood (1993) 1.01
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res (2014) 1.01
Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med (1995) 1.01
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia (2012) 1.00
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia (2014) 1.00
CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells. Eur J Immunol (1994) 0.99
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma (2011) 0.99
Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Int Immunol (1996) 0.96
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia (2011) 0.95
Primary plasma cell leukaemia: immunological and ultrastructural studies in 6 cases. Scand J Haematol (1985) 0.92
Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood (1991) 0.92
Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol (1992) 0.91
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica (2014) 0.89
Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells. Mol Cancer Ther (2004) 0.89
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res (2013) 0.88
Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J Immunother (2009) 0.87
Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol (1995) 0.87
Unusual human lymphoma phenotype defined by monoclonal antibody. J Exp Med (1980) 0.86
An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens. Clin Exp Immunol (1988) 0.86
Autologous stem cell transplantation and multiple myeloma cancer stem cells. Biol Blood Marrow Transplant (2012) 0.86
CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia. J Biol Regul Homeost Agents (2006) 0.86
Surface expression of human myeloma cells: an analysis using a panel of monoclonal antibodies. Acta Haematol (1984) 0.84
Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies. Br J Cancer (1995) 0.84
Two monoclonal antibodies (OKIa1 and OKT10) for the study of the final B cell maturation. J Clin Immunol (1982) 0.83
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica (2016) 0.82
Analysis of T lymphocytes after bone marrow transplantation using monoclonal antibodies. Blood (1982) 0.82
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia (2015) 0.81
Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood (1995) 0.81
Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol (2008) 0.81
CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance. J Clin Pathol (1995) 0.81
Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin Exp Immunol (1997) 0.81
Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics. Br J Haematol (2015) 0.80
Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. Int J Cancer (2009) 0.80
Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules. Br J Cancer (1992) 0.80
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget (2015) 0.79
Solitary pleural plasmacytomas manifested as a massive pleural effusion without evidence of monoclonal gammopathy. Respirology (2008) 0.78
Human myeloma cells express the CD38 ligand CD31. Br J Haematol (1999) 0.78
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1. Blood Cancer J (2012) 0.77
Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. Br J Haematol (1986) 0.77
Analysis of surface antigen expression of human immunoglobulin-secreting cells: phenotypic heterogeneity in normal counterparts of myeloma cells. Br J Haematol (1989) 0.76
Reactivity of monoclonal antibodies with human myeloid precursor cells. Br J Haematol (1981) 0.76
Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. Leuk Lymphoma (2011) 0.76
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. Br J Haematol (2015) 0.75
Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk (2016) 0.75
Extramedullary plasmacytoma: cytological and genotypic studies. Br J Dermatol (1993) 0.75
Assignment of CD38, the gene encoding human leukocyte antigen CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase), to chromosome 4p15. Cytogenet Cell Genet (1995) 0.75